Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Opioid Use Disorder
2025-524778-41-00Phase 2Withdrawn
- Sponsor
- Fondazione Santa Lucia IRCCS
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in opioid use disorder (OUD) and substance use disorder (SUD) comparing Rifaximin (Normix) with Placebo (2 arms). Planned start Apr 2026; status: withdrawn.
02
Drugs
rifaximin
03
Conditions
opioid use disorder (OUD)substance use disorder (SUD)
Beyond the preview
Go deeper on 2025-524778-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524778-41-00.